Over the 20 years I've been treating breast cancer, I think this is the one area where we've really lagged behind in terms of making progress, said Andrew Seidman, MD, attending Physician, Memorial Sloan-Kettering Cancer Center, New York, NY.
“Over the 20 years I’ve been treating breast cancer, I think this is the one area where we've really lagged behind in terms of making progress,” said Andrew Seidman, MD, attending Physician, Memorial Sloan-Kettering Cancer Center, New York, NY.
Dr Seidman says that at the Annual Meeting of the American Society of Clinical Oncologists in Chicago, Aki Morikawa, MD, PhD, Memorial Sloan-Kettering Cancer Center, will present data on two commonly used breast cancer drugs, capecitabine and Lapatinib, to penetrate into breast cancer brain metastases. The observations found in the study should motivate further studies to examine the use of these agents.
This video was taken on May 31, 2013, at the ASCO Annual Meeting 2013 in Chicago, IL.
Results Show Strong Responses for Brentuximab Vedotin Plus Nivolumab Combo in Patients With cHL
December 11th 2023Use of an antibody drug conjugate and a PD-1 inhibitor brings complementary mechanisms together while eliminating the most toxic agent that has been used in combinations to treat classic Hodgkin lymphoma (cHL).
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen